The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults
暂无分享,去创建一个
Joanne S. Robertson | C. Rowe | C. Masters | P. Maruff | D. Ames | R. Pietrzak | Olivier Salvado | S. Laws | V. Villemagne | S. Rainey-Smith | J. Robertson | Y. Lim | K. Harrington | Christa Dang
[1] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[2] A. Woods,et al. Discrepancies between crystallized and fluid ability are associated with frequency of social and physical engagement in community dwelling older adults , 2018, Journal of clinical and experimental neuropsychology.
[3] H. Holling,et al. Retest effects in cognitive ability tests: A meta-analysis , 2018 .
[4] Prashanthi Vemuri,et al. Age, vascular health, and Alzheimer disease biomarkers in an elderly sample , 2017, Annals of neurology.
[5] Timothy J. Hohman,et al. Evaluating Alzheimer's disease biomarkers as mediators of age-related cognitive decline , 2017, Neurobiology of Aging.
[6] Joanne S. Robertson,et al. Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness , 2017, Alzheimer's & dementia.
[7] Joanne S. Robertson,et al. Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging , 2017, Archives of Clinical Neuropsychology.
[8] P. Snyder,et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis , 2016, Alzheimer's & dementia.
[9] Ian M. McDonough,et al. Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease , 2016, Neurobiology of Aging.
[10] Chengjie Xiong,et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. , 2015, JAMA neurology.
[11] Shannon M. Sisco,et al. Predictors of Retest Effects in a Longitudinal Study of Cognitive Aging in a Diverse Community-Based Sample , 2015, Journal of the International Neuropsychological Society.
[12] Stephen R. Aichele,et al. Life span decrements in fluid intelligence and processing speed predict mortality risk. , 2015, Psychology and aging.
[13] Susana Muñoz Maniega,et al. Coupled Changes in Brain White Matter Microstructure and Fluid Intelligence in Later Life , 2015, The Journal of Neuroscience.
[14] D. Y. Lee,et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.
[15] U. Lindenberger. Human cognitive aging: Corriger la fortune? , 2014, Science.
[16] C. Jack,et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study , 2014, The Lancet Neurology.
[17] D. Bates,et al. Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.
[18] Rebecca A Betensky,et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease , 2014, Neurology.
[19] S. Leurgans,et al. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline , 2014, Neurobiology of Aging.
[20] Pierrick Bourgeat,et al. En Attendant Centiloid , 2014 .
[21] C. Rowe,et al. Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.
[22] C. Harada,et al. Normal cognitive aging. , 2013, Clinics in geriatric medicine.
[23] Paul Maruff,et al. The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI , 2013, International Psychogeriatrics.
[24] O. Almkvist,et al. The effect of age on fluid intelligence is fully mediated by physical health. , 2013, Archives of gerontology and geriatrics.
[25] T. Hedden,et al. Meta-analysis of amyloid-cognition relations in cognitively normal older adults , 2013, Neurology.
[26] C. Rowe,et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.
[27] Paul Maruff,et al. Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study , 2012, Journal of clinical and experimental neuropsychology.
[28] Henrik Zetterberg,et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.
[29] Philip S. Insel,et al. CSF biomarker and PIB-PET–derived beta-amyloid signature predicts metabolic, grey matter and cognitive changes in nondemented subjects , 2011, Alzheimer's & Dementia.
[30] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[31] J. Morris,et al. Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.
[32] R. Mayeux,et al. Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.
[33] T. Salthouse. Selective review of cognitive aging , 2010, Journal of the International Neuropsychological Society.
[34] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[35] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[36] A. Fagan,et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.
[37] W. Mittenberg,et al. Changes in intellectual functioning associated with normal aging. , 2009, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.
[38] C. Rowe,et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.
[39] I. Deary,et al. Age-related Changes in Memory and Fluid Reasoning in a Sample of Healthy Old People , 2009, Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.
[40] R. de Raedt,et al. Differentiation Between Dementia and Depression Among Older Persons: Can the Difference Between Actual and Premorbid Intelligence Be Useful? , 2008, Journal of geriatric psychiatry and neurology.
[41] R. Lipton,et al. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease , 2008, Journal of the International Neuropsychological Society.
[42] W. Burns,et al. Discrepancies between Premorbid and Current IQ as a Function of Progressive Mental Deterioration , 2005, Perceptual and motor skills.
[43] C. Jack,et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.
[44] Enrico Simonotto,et al. The functional anatomy of inspection time: an event-related fMRI study , 2004, NeuroImage.
[45] Wolfgang Prinz,et al. Transformations in the Couplings Among Intellectual Abilities and Constituent Cognitive Processes Across the Life Span , 2004, Psychological science.
[46] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[47] R. Snaith,et al. The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.
[48] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[49] L. Cronbach,et al. How we should measure "change": Or should we? , 1970 .
[50] Ninoslav Mimica,et al. Dementia: a public health priority , 2019 .
[51] C. Rowe,et al. Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. , 2017, Journal of Alzheimer's disease : JAD.
[52] F. Craik,et al. 50 Years of Cognitive Aging Theory. , 2016, The journals of gerontology. Series B, Psychological sciences and social sciences.
[53] P. Sachdev,et al. Influence of population versus convenience sampling on sample characteristics in studies of cognitive aging. , 2014, Annals of epidemiology.
[54] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[55] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .
[56] O. Almkvist,et al. Cognitive decline from estimated premorbid status predicts neurodegeneration in Alzheimer's disease. , 2009, Neuropsychology.
[57] J. J. Ryan,et al. Wechsler Adult Intelligence Scale-III , 2001 .
[58] O. Spreen,et al. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary , 1991 .
[59] R. Cattell,et al. Age differences in fluid and crystallized intelligence. , 1967, Acta psychologica.